Correlation between clinical severity and quality of life in moderate to severe psoriasis patients: real-world evidence
Abstract
Background/Aim. Psoriasis is a chronic multisystem, inflammatory, and immune-mediated dermatological disease of a relapsing nature. Not only does it affect objective parameters such as skin and joints, with different intensity involvement and with changes and the degree of changes, but it also significantly affects the health-related quality of life (QoL). The aim of the study was to determine the clinical severity and QoL of patients with moderate to severe psoriasis and examine the association between those parameters before and after the treatment. Methods. This cross-sectional study included 183 patients diagnosed with moderate to severe psoriasis. The severity of the clinical picture was determined by calculating the Psoriasis Area and Severity Index (PASI) by a dermatologist, while the QoL was assessed using the Dermatology Life Quality Index (DLQI) questionnaire and psoriasis-related stress by the Psoriasis Life Stress Inventory (PLSI). Disease severity and QoL were measured at the baseline visit and after the 16th week of therapy. Results. The average PASI score at the beginning of therapy was 23.1 ± 6.5, while after 16 weeks, this value was 4.36 ± 4.86. The DLQI score was 20.8 ± 5.0 at the start of therapy and 6.20 ± 6.16 after 16 weeks, while the PLSI score was 35.37 ± 8.84 initially and 12.75 ± 12.82 after 16 weeks of therapy. A strong correlation was found between PASI and PLSI scores (r = 0.702, р < 0.001) in the 16th week of therapy, while the correlation between DLQI and PASI scores was moderate (r = 0.683, р < 0.001). No significant differences between PASI and DLQI scores were found (r = 0.080, р = 0.284) nor between PASI and PLSI scores (r = 0.109, р = 0.140) at baseline. Conclusion. Patients with severe psoriasis experience a significant reduction in their QoL, accompanied by a high level of psychosocial stress. Observed improvements in QoL have shown a moderate correlation, while lower levels of psychosocial stress have strongly correlated with the severity of the clinical presentation, which may indicate a complex interaction between psychological factors and physical health in patients with psoriasis.
References
AlQassimi S, AlBrashdi S, Galadari H, Hashim MJ. Global bur-den of psoriasis - comparison of regional and global epidemi-ology, 1990 to 2017. Int J Dermatol 2020; 59(5): 566–71.
Nagpal N, Gordon-Elliott J, Lipner S. Comparison of quality of life and illness perception among patients with acne, eczema, and psoriasis. Dermatol Online J 2019; 25(5): 13030/qt3fk3f989.
Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol 2020; 82(1): 117–22.
Golbari NM, Porter ML, Kimball AB. Current guidelines for psoriasis treatment: a work in progress. Cutis 2018; 101(3S): 10–2.
Paudyal P, Apfelbacher C, Jones C, Siddiqui S, El-Turki A, DeGio-vanni C, et al. "DLQI Seems to be 'Action', and Skindex-29 Seems to be 'Emotion'": Qualitative Study of the Perceptions of Patients with Psoriasis or Eczema on Two Common Der-matology-specific Quality of Life Measures. Acta Derm Vene-reol 2020; 100(8): 1–6.
Park SY, Kim KH. What Factors Influence on Dermatology-Related Life Quality of Psoriasis Patients in South Korea? Int J Environ Res Public Health 2021; 18(7): 3624.
Atayoglu AT, Çapar AG, Basmisirlioglu E, Yasar Y, Aykemat Y, Guner Atayoglu A, et al. Investigation of the Relationship be-tween the Disease Severity and Quality of Life of Psoriasis Pa-tients and Their Anthropometric Measurements and Diets. Healthcare (Basel) 2022; 10(11): 2323.
Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol 2014; 28(3): 333–7.
Gundogdu M, Kundakci N. Evaluation of the correlation be-tween scales determining disease severity in patients with moderate-severe chronic plaque-type psoriasis. J Cosmet Dermatol 2021; 20(7): 2328–31.
Milčić D, Janković S, Vesić S, Milinković M, Janković J. Assessment of quality of life in patients with psoriasis: a study from Serbia. Int J Dermatol 2015; 54(5): 523–8.
World Medical Association. World Medical Association Declara-tion of Helsinki: ethical principles for medical research involv-ing human subjects. JAMA 2013; 310(20): 2191–4.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19(3): 210–6.
Gupta MA, Gupta AK. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. Acta Derm Vene-reol 1995; 75(3): 240–3.
Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica 1978; 157(4): 238–44.
Balato A, Zink A, Babino G, Buononato D, Kiani C, Eyerich K, et al. The Impact of Psoriasis and Atopic Dermatitis on Quality of Life: A Literature Research on Biomarkers. Life (Basel) 2022; 12(12): 2026.
Misery L, Chesnais M, Merhand S, Aubert R, Bru MF, Legrand C, et al. Perceived stress in four inflammatory skin diseases: an analysis of data taken from 7273 adult subjects with acne, atopic dermatitis, psoriasis or hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2022; 36(8): e623–6.
Owczarek W, Walecka I, Nowakowska A, Ciechanowicz P, Reich A, Lesiak A, et al. Effectiveness of infliximab biosimilars in the treatment of moderate to severe chronic plaque psoriasis: ex-perience of real-world data from the register of the program "Treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland. Adv Dermatol Alergol 2022; 39(4): 723–8.
Gorelick J, Shrom D, Sikand K, Renda L, Burge R, Dworkin C, et al. Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey. Dermatol Ther (Heidelb) 2019; 9(4): 785–97.
Zhong H, Yang H, Mao Z, Chai X, Li S. Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study. Health Qual Life Outcomes 2021; 19(1): 271.
Herédi E, Rencz F, Balogh O, Gulácsi L, Herszényi K, Holló P, et al. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. Eur J Health Econ 2014; 15(Suppl1): S111–9.
Lacour JP, Bewley A, Hammond E, Hansen JB, Horne L, Paul C, et al. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL). Dermatol Ther (Heidelb) 2020; 10(5): 1099–109.
Prevezas C, Katoulis AC, Papadavid E, Panagakis P, Rigopoulos D. Short-Term Correlation of the Psoriasis Area Severity Index, the Nail Psoriasis Area Severity Index, and the Dermatology Life Quality Index, before and after Treatment, in Patients with Skin and Nail Psoriasis. Skin Appendage Disord 2019; 5(6): 344–9.
Silva MF, Fortes MR, Miot LD, Marques SA. Psoriasis: correla-tion between severity index (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treat-ment. An Bras Dermatol 2013; 88(5): 760–3.
Rigas HM, Bucur S, Ciurduc DM, Nita IE, Constantin MM. Psy-chological Stress and Depression in Psoriasis Patients - a Dermatologist's Perspective. Maedica (Bucur) 2019; 14(3): 287–91.